Alchemab raised $32m in Series A extension funding from OVI, RA Capital, SV Health Investors, DCVC Bio , Lightstone Ventures, and Eli Lilly.
03 September 2025
03 September 2025
Total investments received (USD): 115.01M
Round value (USD): 32M
Company: Alchemab
Industry: BiotechHealth services
Related deals
T-Therapeutics in a $32 million series A extension with Tencent, BGF, Sofinnova, F-Prime, Digitalis Ventures, Cambridge Innovation, Sanofi.
Investments
03 November 2025
Cyted Health raises €37.5 million in a Series B financing round led by EQT Life Sciences, Advent Life and British Business Bank, w/ Morningside and BGF.
Investments
01 August 2025
Portal Biotech raised $35m Series A round co-led by NATO and Earlybird, joined by SCVC, Pillar VC, 8VC, Amino Collective, Outsized, We Venture Capital.
Investments
20 June 2025
Laverock Therapeutics raised €23.3m in seed funding led by Calculus Capital, joined by Eli Lilly, Mercia Ventures, Eos Advisory, Maven Capital and Norcliffe.
Investments
01 June 2025
Netherlands
Austria
Switzerland
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Ireland
Italy
Portugal